Lawsuit Alert: Investors who lost money with shares of Immutep Limited (NASDAQ: IMMP) should contact the Shareholders Foundation

An investor, who purchased shares of Immutep Limited (NASDAQ: IMMP), filed a lawsuit over alleged violations of Federal Securities Laws by Immutep Limited in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Immutep Limited (NASDAQ: IMMP) have certain options and for certain investors are short and strict deadlines running. Deadline: July 6, 2026. NASDAQ: IMMP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Sydney, Australia based Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Immutep's TACTI-004 Phase III trial evaluated eftilagimod alfa (efti) in patients with advanced lung cancer.

On March 13, 2026, defendants allegedly announced that the Independent Data Monitoring Committee ("IDMC") for the TACTI-004 Phase III study evaluating efti in patients in first line non-small cell lung cancer recommended discontinuing the trial following a planned interim futility analysis. Defendants further allegedly announced that, "[b]ased on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility."

Shares of Immutep Limited (NASDAQ: IMMP) declined from $3.53 per share on December 08, 2025, to as low as $0.29 per share on April 13, 2026.

The plaintiff claims that between March 24, 2025 and March 12, 2026, the defendants made false and/or misleading statements and/or failed to disclose that the defendants concealed and misrepresented the status and prospects of the TACTI-004 trial based on continuing positive efficacy and safety readouts of efti's performance in other trials, particularly following positive top-line results from Immutep's prior TACTI-002 and INSIGHT-003 studies, that the defendants announced that the trial was exhibiting "strong operational progress" and the planned interim futility analysis remained "on track for the first quarter of CY2026", and that Immutep was aware of or was reckless, based on its access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints.

Those who purchased shares of Immutep Limited (NASDAQ: IMMP) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.